While Metsera is offering less shares, 15.3 million, than the 17.2 million it had planned in recent days, the final IPO price of $18 per share has exceeded the $15-$17 range it had initially expected.

Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement. It had offered 17.2 million shares for $15 to $17 each.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement. It had offered 17.2 million shares for $15 to $17 each.

Metsera is also not the first biotech to file for an IPO this year, following kidney-disease-focused Maze Therapeutics, which revealed plans for a public debut Jan. 7.

A week after the first IPO of the year was priced, obesity treatment developer Metsera Inc. and renal specialist Maze Therapeutics Inc. have begun trading on Nasdaq. Metsera (NASDAQ:MTSR) surged 47% ...

Odyssey first filed for an IPO in January alongside fellow Massachusetts biotech Sionna Therapeutics. The latter company pushed through with its offering, landing on the Nasdaq floor with $219.2 ...

On the same day as Metsera’s filing, Maze Therapeutics also outlined plans for a $131m Nasdaq IPO, while Ascentage Pharma – already listed in Hong Kong – started trading in the US last week ...

Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement Bloomberg Terminal It had offered 17.2 million shares for $15 to $17 each.